Browsing by Author McIntyre P

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 10 of 10
Publication DateTitleAuthor(s)TypeSubject
24-May-202010-Valent pneumococcal non-typeable H. influenzae protein D conjugate vaccine (PHiD-CV10) versus 13-valent pneumococcal conjugate vaccine (PCV13) as a booster dose to broaden and strengthen protection from otitis media (PREVIX_BOOST) in Australian Aboriginal children: study protocol for a randomised controlled trial.Oguoma VM; Wilson N; Mulholland K; Santosham M; Torzillo P; McIntyre P; Smith-Vaughan H; Balloch A; Chatfield M; Lehmann D; Binks MJ; Chang A; Carapetis JR; Krause VL; Andrews RM; Snelling T; Licciardi P; Morris PS; Leach AJJournal Article- 
8-Nov-2024Erratum to "Real world impact of 13vPCV in preventing invasive pneumococcal pneumonia in Australian children: A national study" [Vaccine 41(1) (2023) 85-91].Homaira N; Strachan R; Quinn H; Beggs S; Bhuiyan M; Bowen A; Fawcett L K; Gilbert G L; Lambert S B; Macartney K; Marshall H S; Martin A C; McCallum G; McCullagh A; McDonald T; Selvadurai H; McIntyre P; Oftadeh S; Ranganathan S; Saunders T; Suresh S; Wainwright C; Wilson A; Wong M; Jaffe A; Snelling TPublished Erratum- 
27-Nov-2015Evaluation of impact of 23 valent pneumococcal polysaccharide vaccine following 7 valent pneumococcal conjugate vaccine in Australian Indigenous children.Jayasinghe S; Chiu C; Menzies R; Lehmann D; Cook H; Giele C; Krause VL; McIntyre PJournal Article; Observational StudyIndigenous; Invasive pneumococcal disease epidemiology; Pneumococcal conjugate vaccine; Pneumococcal disease; Pneumococcal polysaccharide vaccine 
30-Jan-2023Key lessons from the COVID-19 public health response in Australia.Basseal JM; Bennett CM; Collignon P; Currie BJ; Durrheim DN; Leask J; McBryde ES; McIntyre P; Russell FM; Smith DW; Sorrell TC; Marais BJJournal Article; Review; Journal Article; Review- 
20-Jun-2019'Links2HealthierBubs' cohort study: protocol for a record linkage study on the safety, uptake and effectiveness of influenza and pertussis vaccines among pregnant Australian women.Sarna M; Andrews RM; Moore H; Binks MJ; McHugh L; Pereira GF; Blyth CC; Van Buynder P; Lust K; Effler P; Lambert SB; Omer SB; Mak DB; Snelling T; D'Antoine HA; McIntyre P; de Klerk N; Foo D; Regan AKJournal Articleantenatal; immunisation; vaccine 
15-Jan-2017Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014.Jayasinghe S; Menzies R; Chiu C; Toms C; Blyth CC; Krause VL; McIntyre PHistorical Article; Journal ArticleAustralia; PCV13; PCV7; invasive pneumococcal disease; vaccine impact. 
7-Aug-2019Long-term impact of pneumococcal conjugate vaccines on invasive disease and pneumonia hospitalisations in Indigenous and non-Indigenous Australians.Meder KN; Jayasinghe S; Beard F; Dey A; Kirk M; Cook H; Strachan J; Sintchenko V; Smith H; Giele C; Howden B; Krause VL; McIntyre PJournal ArticleAustralia; impact; invasive pneumococcal disease; pneumococcal conjugate vaccines; pneumococcal pneumonia 
16-Jan-2015Pneumococcal conjugate vaccines PREVenar13 and SynflorIX in sequence or alone in high-risk Indigenous infants (PREV-IX_COMBO): protocol of a randomised controlled trial.Leach AJ; Mulholland EK; Santosham M; Torzillo PJ; Brown NJ; McIntyre P; Smith-Vaughan H; Skull S; Balloch A; Andrews RM; Carapetis J; McDonnell J; Krause VL; Morris PSComparative Study; Journal Article; Randomized Controlled TrialIMMUNOLOGY; MICROBIOLOGY; PUBLIC HEALTH 
15-Nov-2022Real world impact of 13vPCV in preventing invasive pneumococcal pneumonia in Australian children: A national study.Homaira N; Strachan R; Quinn H; Beggs S; Bhuiyan M; Bowen A; Fawcett L; Gilbert GL; Lambert SB; Macartney K; Marshall HS; Martin Md AC; McCallum G; McCullagh A; McDonald T; Selvadurai H; McIntyre P; Oftadeh S; Ranganathan PhD S; Saunders T; Suresh S; Wainwright C; Wilson A; Wong M; Jaffe A; Snelling TJournal Article13vPCV effectiveness; Children; Invasive pneumococcal pneumonia 
4-May-2018Sub-optimal protection against past hepatitis B virus infection where subtype mismatch exists between vaccine and circulating viral genotype in northern Australia.Cheah BC; Davies J; Singh GR; Wood N; Jackson K; Littlejohn M; Davison B; McIntyre P; Locarnini S; Davis JS; Tong SYCJournal ArticleAboriginal; Genotype; Hepatitis B virus; Indigenous; Vaccine effectiveness 
Showing results 1 to 10 of 10